The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC).
 
Ryan Sugarman
No Relationships to Disclose
 
Marc Botteman
Employment - OPEN Health
Leadership - OPEN Health
Consulting or Advisory Role - Bayer Health (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Helsinn Therapeutics (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Bayer Health (Inst); Bristol Myers Squibb Foundation (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Helsinn Therapeutics (Inst); Merck Sharp & Dohme (Inst)
Other Relationship - OPEN Health; Pharmerit
 
Nifasha Rusibamayila
No Relationships to Disclose
 
Hiep Nguyen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Daniel Lin
Consulting or Advisory Role - Exelixis; Exelixis/Ipsen